Containers for storing body fluids

A container with a PFPA primer coating and copolymer stabilizes body fluids by preventing interactions with the tube walls, ensuring accurate analysis results by maintaining fluid integrity.

JP7600355B2Active Publication Date: 2024-12-16DC DIAGNOSTICS CONCEPT UG HAFTUNGSBESCHRANKT
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2023210373
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-01
Filing Date
2023-12-13
Publication Date
2024-12-16
Estimated Expiration
2040-02-03

AI Technical Summary

Technical Problem

Existing containers for storing body fluids, such as blood collection tubes, suffer from issues like protein adsorption, cell adhesion, and coagulation due to interactions with the tube walls, leading to unreliable analytical results and limited retention times, which conventional additives like EDTA and heparin cannot fully address.

Method used

A container with a primer coating composed of perfluorophenyl azide (PFPA) and a copolymer like poly(N-vinylamine-co-N-vinylacetamide) is used, which forms a stable covalent bond with the container surface, preventing unwanted interactions and allowing a second coating to adhere effectively, thereby stabilizing the body fluids.

Benefits of technology

The primer coating prevents alteration processes in body fluids, ensuring accurate diagnostic and therapeutic decisions by maintaining the integrity of the fluid composition during storage.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007600355000001
    Figure 0007600355000001
  • Figure 0007600355000002
    Figure 0007600355000002
  • Figure 0007600355000003
    Figure 0007600355000003
Patent Text Reader

Abstract

To develop an alternative container for storing a body fluid, the container being characteristic in primer coating improving a joint of the second coating onto the contact surface of the container.SOLUTION: A container (1) for storing a body fluid is a blood collection tube (2) having an inner space (4) for receiving the body fluid and a wall (5) surrounding the inner space (4). The surface of the wall (5) facing the inner space (4) of the container (1) forms a contact surface (6), and at least a part of the contact surface (6) is provided with a primer coating (7), which is formed from a perfluorophenyl azide (PFPA) having azide groups and functional groups.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Introduction The present invention relates first to a container for storing a body fluid, in particular a blood collection tube having an internal space for containing the body fluid and a wall surrounding the internal space, in which the surface of the wall facing the internal space of the container forms a contact surface, and at least a part of the contact surface is provided with a primer coating, the primer coating being formed from a fluorinated coupling agent in the form of perfluorophenyl azide (PFPA) having an azide group and a functional group.

[0002] The present invention further relates to a method for coating the contact surface of a container for storing a body fluid.

[0003] Prior Art In the diagnostic process, the characterization of quantitative biomarker concentrations and activities in blood and other body fluids (extravascular fluid (EVF)) and the morphology of cells and particles together with the medical history allows a clinical diagnostic decision to be made. A prerequisite for reliable decision-making is the highest possible pre-analytical stabilization of blood and EVF after collection from the blood vessels and their ex vivo storage until analysis. Currently, samples taken from body fluids are stored in glass or plastic tubes, usually made of polypropylene (PP), until the actual analysis. Here, numerous alteration processes occur for all components of these body fluids, especially blood, after they leave the patient's body. Inside the tube, the contact of the collected body fluid with the walls of the tube leads, among other things, to protein adsorption, cell adhesion and coagulation of the body fluid. To stabilize the numerous different components, their concentrations and activities (e.g. in blood), it is a normal procedure to add additives to the tubes, for example EDTA, citrate or heparin. However, not all additives are suitable for all biomarkers, so the treating physician must choose a special tube depending on the suspected disease. Furthermore, the retention time in the container, heat resistance, or even exposure to light is very limited, and if exceeded, may likewise lead to erroneous analytical results. Also, additives such as EDTA, citrate, or heparin can only inhibit blood clotting. Many other aspects of the degradation process cannot be prevented.

[0004] A container for storing body fluids is shown in EP 1199104. There, a polypropylene blood collection tube is disclosed that reduces adhesion of blood components to the contact surface of the blood collection tube. Suitable coating materials are hydrophilic polymers polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone (PVP), polystyrene sulfonate and copolymers thereof, and combinations thereof. These hydrophilic polymers are applied to the inside of the blood collection tube by a spraying or dipping process, and then dried in air or an oven and crosslinked by radiation. The blood collection tube may also contain additives that promote or inhibit blood clotting.

[0005] US Patent 5,830,539 discloses a method for functionalizing and coating a substrate. The coating is said to be suitable for increasing the biocompatibility of the substrate. In this case, a first functionalizing reagent is applied to the substrate, whereby a covalent bond to the substrate is said to occur by addition of a nitrene. For this purpose, the first functionalizing reagent has an azide group and a first functionalizing group, for example an active ester, where the azide group is intended to react with the substrate, while the first functionalizing group allows the binding of a second functionalizing reagent to the first functionalizing reagent. The second functionalizing reagent likewise has a functionalizing group that binds to the substrate, for example an enzyme, an antibody, a diagnostic or therapeutic agent. The substrate coated in this way thus allows the binding of biological and endogenous substances, for example enzymes, hormones, antibodies, nucleic acids, peptides or amino acids. As preferred functionalizing reagents, N-hydroxysuccinimide-active ester-functionalized perfluorophenyl azides (NHS-PFPAs) are intended.

[0006] However, it turns out that the derivatization of perfluorophenyl azides with NHS is a drawback of known containers, as they are not suitable for use in liquid media, especially blood and EVF, due to the moisture sensitivity of NHS, and in particular such derivatized perfluorophenyl azides require appropriate stabilization.

[0007] assignment The object of the present invention is to develop an alternative container for storing body fluids, which is characterized by a primer coating that improves the bonding of a second coating to the contact surface of the container.

[0008] It would be desirable for this problem to be solved by the method according to the invention as well.

[0009] solution Starting from the container for storing body fluids described at the beginning, the above object is achieved by binding a copolymer composed of poly(N-vinylamine-co-N-vinylacetamide) to the functional groups of the primer coating.

[0010] With regard to the hydrophobicity of the contact surfaces in contact with blood and extravascular fluids, such coatings are particularly advantageous, since typical contact surfaces, such as those made of polypropylene, are well suited for use as materials for blood collection tubes due to their chemically inert properties, but are difficult to coat due to the hydrophobic nature of this material. In particular, the application of aqueous solutions and substances becomes more difficult, since the surface is not completely wetted, which inhibits the binding of aqueous chemicals that prevent degradation processes of blood and other body fluids.

[0011] Phenyl azides belong to the most validated coupling agents due to their high reaction efficiency, fast kinetics, excellent storage stability, and ease of preparation. Here, fluorinated phenyl azides, especially perfluorophenyl azide (PFPA), act as heterobifunctional crosslinkers. Perfluorophenyl azides are photoaffinity coupling reagents that allow for surface modification as well as crosslinking and bonding of polymers. Perfluorophenyl azides were prepared by derivatizing pentafluorobenzoic acid methyl ester with sodium azide (NaN3). Perfluorophenyl azides can be efficiently and reproducibly utilized for coupling with a wide range of molecules and materials because their functional groups react with carbon-hydrogen bonds, ammonium-hydrogen bonds, or carbon-carbon bonds, and are therefore highly versatile.

[0012] Due to its attractive heterobifunctionality, perfluorophenylazide acts as an adhesion promoter and coupling agent for the contact surface of the container and the second coating. On the one hand, the fluorinated phenylazide can form a stable covalent bond with the tube wall through its azide group. On the other hand, the substrate-reactive functional group "-R" of the fluorinated phenylazide allows customized bonding of statistical copolymers, which according to the present invention consist of poly(N-vinylamine-co-N-vinylacetamide). In this case, the perfluorophenylazide is not further derivatized, in contrast to known primer coatings.

[0013] A particular advantage of the container according to the invention is therefore that the primer coating can, on the one hand, bind to the contact surface of the container and, on the other hand, form a bond to further coatings, thereby preventing detrimental processes for blood components and extravascular body fluids. In summary, the reactivity of perfluorophenylazide and its functional groups allows selective and sequential coupling reactions in which molecules and surface substances of different natures can be bound. Here, the primer coating according to the invention, in contrast to known primer coatings, has the effect of actually blocking the binding of biological and endogenous substances, thus preventing any adhesion or adsorption of biological and endogenous substances.

[0014] Here, the binding of the perfluorophenyl azide to the contact surface of the blood collection tube is possible, in particular, through the azide groups of the perfluorophenyl azide, which can be activated by suitable treatment to form an irreversible chemical bond with the surface of the container. Furthermore, the amino groups of the copolymer are acid-hydrolyzed in a chemical reaction. By adding suitable chemicals, the amino groups of the copolymer can be functionalized, so that they serve as site-selective binding sites, so-called anchor points, for the second coating. The second layer can therefore be applied particularly easily to the previous primer coating, advantageously without any difficulties in this case with regard to the wettability of the substance to the contact surface of the container. Overall, the second coating can be permanently bonded to the inert wall of the container.

[0015] The primer coating according to the invention is particularly advantageous in that the functional groups of perfluorophenyl azide are formed from statistical copolymers, namely poly(N-vinylamine-co-N-vinylacetamide). Experiments have shown that such copolymers are particularly suitable for stabilizing the phenyl rings of perfluorophenyl azide and suppressing the excessive electrophilicity of perfluorophenyl azide, thus suppressing undesirable chemical reactions of perfluorophenyl azide. Here, the polyamide polymer itself does not interact with blood or extravascular fluids.

[0016] According to a preferred embodiment of the container, it is provided that the container is made of plastic, advantageously polypropylene, polystyrene, polyethylene, polymethylmethacrylate, polyimide or glass. The aforementioned materials are commonly used in the medical field and have so far proved to be particularly advantageous for the manufacture of disposable products due to their low manufacturing costs.

[0017] In a preferred embodiment of the invention, it is provided that the container has a second coating comprising a PEG / PEO-PPO copolymer, poly-(3-methacryloylaminopropyl)-(2-carboxyethyl)-dimethylammonium carboxybetaine methylacrylamide (pCBMAA-1), or a polypeptide-based block copolypeptide, the second coating being combined with the primer coating.

[0018] The second coating is in direct contact with the blood or extravascular fluid but does not undergo any chemical reaction, which advantageously prevents the body fluid being tested from being altered prior to laboratory analysis, resulting in deviations in quantity or quality from the actual composition of the blood or body fluid.

[0019] The PEG / PEO-PPO copolymers are advantageously composed of star-shaped 6-arm polyethylene glycols or polyethylene oxides (PEG or PEO) modified with specific propylene oxides (PPO) to prevent the crystallization of the polymer. According to an advantageous embodiment of the invention, it is now provided that the copolymers can be bonded by their isocyanate groups to the amino groups of the primer coating.

[0020] Poly-(3-methacryloylaminopropyl)-(2-carboxyethyl)-dimethylammonium carboxybetaine methylacrylamide (pCBMAA-1) is electrically neutral, zwitterionic and cosmotropic. The bonding with the primer coating is carried out by radical polymerization. Advantageously, an electron transfer reaction (SET-LRP, Single-Electron Transfer Living Radical Polymerization) is used.

[0021] The polypeptide-based block copolypeptides are produced using recombinant DNA technology. Advantageously, they are composed of an elastin-polypeptide construct that is electrically neutral and protein-repellent. The polypeptide construct is charged, which results in the binding of the construct to a primer-coated (negative charge) or plasma-treated surface (positive charge) depending on the charge selectivity. Similarly, zwitterionic polypeptide-based block copolypeptides and electrically neutral constructs are also contemplated.

[0022] Advantageously, the container has a sealing lid or sealing cap, advantageously made of polyethylene (PE), for hermetically sealing the body fluid in the container. It is also conceivable that the sealing cap is provided with a membrane that can be pierced by a needle to allow the body fluid to enter the container. When taking blood from a patient's vein, it is advantageous to place the container under reduced pressure. This allows the blood to be drawn into the container by the negative pressure after piercing the patient's vein with a needle connected to a needle inserted into the container via a tube. Alternatively, the container has a piston rod with a piston arranged in the interior space, the movement of which draws the body fluid into the container. Advantageously, the sealing lid is made of polyethylene (PE) and the piston rod is made of polystyrene (PS).

[0023] In a preferred embodiment of the container according to the invention, the sealing lid is likewise provided with a second coating, as is the piston described above.

[0024] The problem mentioned at the outset is solved by a method for coating the contact surface of a container for storing body fluids by two process steps. The first process step comprises applying a perfluorophenyl azide having an azide group and a functional group to the contact surface of the container, the primer coating being formed from a perfluorophenyl azide having an azide group and a functional group (PFPA). The second process step comprises treating the perfluorophenyl azide, whereby the azide groups of the perfluorophenyl azide bond to the contact surface of the container, thereby producing a coating that is inseparably bonded to the contact surface.

[0025] The advantage of this method, as well as the container according to the invention, is that a primer coating is created that is particularly well suited for the bonding of a second coating, which in this case prevents undesirable processes of deterioration of the body fluid in the container. This behavior is desirable in that it ensures a high stabilization of the body fluid in the container and thus provides the prerequisites for making it possible to make a correct clinical decision (diagnostic or therapeutic decision).

[0026] Advantageously, an activation step is provided for improving the adhesion of the primer coating to the contact surface of the container, which activation step is advantageously carried out before the first process step, and / or an activation step is provided for improving the adhesion of the second coating to the primer coating, which activation step is advantageously carried out after the second process step.

[0027] Advantageously, at least one activation step is carried out by UV or plasma treatment, where plasma is formed from noble gas, preferably argon, or oxygen. This plasma treatment causes controlled decomposition of the outermost layer of polypropylene. As a result, the zeta potential becomes negative, which further improves the adhesion of the primer coating. This behavior is desirable in that it allows the concentration of perfluorophenyl in the applied solution to be reduced.

[0028] It was found that polypeptide-based block copolypeptides consisting of elastin-polypeptide constructs with electrically positively charged polypeptides bind particularly well to the plasma-treated layer. The same is true for zwitterionic polypeptide-based block copolypeptides with electrically positively charged polypeptide components. On the other hand, polypeptide-based block copolypeptides consisting of elastin-polypeptide constructs with electrically negatively charged polypeptides bind particularly well to the primer coating.

[0029] Furthermore, the plasma treatment results in the formation of nucleophilic groups, which is particularly advantageous for the second coating, so that the second coating can bond particularly well to the contact surface of the container, even without a prior primer coating.

[0030] Advantageously, the first process step is carried out by introducing perfluorophenyl azide into a vessel or by bubbling perfluorophenyl azide into the vessel.

[0031] The chemicals may be present in liquid form or may be processed into an aqueous solution based on their water solubility. It is advantageous to fill the container with the chemicals and wet the contact surfaces of the container with the respective substances. The excess liquid is then poured off and removed from the container. It is also conceivable to apply the chemicals to the contact surfaces by a spraying process. In any case, it is ensured that the contact surfaces of the container are completely wetted with the chemicals.

[0032] In a preferred embodiment of the method according to the invention it is provided that the second process step is carried out by means of energy rays, advantageously ultraviolet light, laser light or electron beams.

[0033] Here, the bonding between the primer coating and the wall of the container to be coated is initiated by functionalizing the azide groups with UV irradiation. When the azide groups are activated by UV irradiation, they form covalent bonds at the bonding sites with the container wall. Upon photoactivation, the azide groups generate highly reactive radical intermediates that can then form stable covalent bonds with adjacent surface molecules.

[0034] The advantages mentioned with respect to the container according to the invention are likewise achieved by the method described above.

[0035] The present invention provides that the second coating can also be applied to and bonded to the contact surface of the container without a prior primer coating. In such embodiments, the contact surface can be plasma treated to improve bonding. In either case, when any of the aforementioned materials come into contact with the contact surface of the container, negatively charged nucleophilic groups are formed, which form a stable bond with the contact surface.

[0036] Bonding the second coating directly to the contact surface of the container advantageously allows the container to be coated in one step and also reduces the cost of manufacturing such containers.

[0037] Exemplary embodiments: The invention as described above will now be explained in more detail with reference to exemplary embodiments shown in the drawings. [Brief description of the drawings]

[0038] [Figure 1] 3 is a three-dimensional view of a blood collection tube according to the present invention. [Diagram 2] Vertical cross section of the blood collection tube in FIG. [Diagram 3] FIG. 2 is a diagram showing the structural formula of a primer coating.

[0039] 1 shows a first container 1 according to the invention in the form of a blood collection tube 2 for storing a patient's blood sample, which is made of polypropylene and is provided with a primer coating and a second coating to stabilize the blood sample. Furthermore, the blood collection tube 2 is provided with a sealing lid 3 at one end. The sealing lid 3 hermetically seals the blood collection tube 2, ensuring secure storage and preventing possible blood-environment interactions.

[0040] FIG. 2 shows a vertical cross-sectional view of the blood collection tube 2 shown in FIG. 1. The wall 5 of the blood collection tube 2 facing the internal space 4 forms a contact surface 6 between the blood and the wall 5 of the blood collection tube 2. The contact surface 6 is provided with a primer coating 7 made of perfluorophenylazide (PFPA) having an azide group 9 and a functional group 10, to which a copolymer made of poly(N-vinylamine-co-N-vinylacetamide) is bonded. Additionally, the blood collection tube 2 has a second coating 8 adjacent to and bonded to the primer coating 7.

[0041] To apply the perfluorophenyl azide to the contact surface 6 of the blood collection tube 2 according to the first process step, this perfluorophenyl azide is introduced into the blood collection tube 2 as an aqueous solution with a concentration of 5-10 mg / mL. Naturally, the perfluorophenyl azide may also be present in the solution at other concentrations. In any case, due to the high affinity of perfluorophenyl azide for polypropylene, given by the hydrophobicity of perfluorophenyl azide, this solution wets the contact surface 6 of the blood collection tube 2. The remainder of the perfluorophenyl azide that has accumulated as excess liquid in the blood collection tube 2 is removed from the blood collection tube 2.

[0042] In a second process step, the applied solution is bound to the blood collection tube 2 by means of UV light. In the process, the perfluorophenylazide is activated in such a way that its azide groups 9 are irreversibly bound to the contact surface 6 of the container 1. This is possible in particular by radicalization of N3 to N°. In a chemical reaction, the formamide groups of the copolymer are hydrolyzed by acid.

[0043] The blood collection tube 2 is then applied with a second coating 8, which consists of a PEG-PPO block copolymer, which is composed of a six-arm star-shaped polyethylene glycol (PEG) and a specific propylene oxide (PPO) modification to prevent the polymer from crystallizing. The copolymer is also present as an aqueous solution. It is applied in a manner similar to the first process step. In this case, the isocyanate groups of the PEG-PPO copolymer are bonded to the amino groups 13 of the primer coating 7. To strengthen this bond, the inner wall 5 of the blood collection tube 2 is additionally treated with UV light. It is also conceivable to strengthen it by a plasma treatment.

[0044] The layer thicknesses of the coatings 7, 8 shown in FIG. 2 have been exaggerated for clarity and are therefore not drawn to scale.

[0045] 3 shows the structural formula of primer coating 7, which includes azide group 9 and functional group 10, where azide group 9 of perfluorophenylazide is attached to wall 5 of container 1. Functional group 12 of perfluorophenylazide is encapsulated in copolymer 11 by bonding poly(N-vinylamine-co-N-vinylacetamide) of copolymer 11 to functional group 10 of perfluorophenylazide. Amino group 13 provided by copolymer 11 now serves as an anchor point to second coating 8. [Explanation of symbols]

[0046] 1 container 2 Blood collection tube 3 Sealing lid 4. Interior space 5. Wall 6 Contact surface 7 Primer Coating 8 Second Coating 9 Azide group 10 Functional groups 11 Copolymer 12 Functional groups 13 Amino group

Claims

[Claim 1] A container (1') for storing a body fluid, in particular a blood collection tube (2) having an internal space (4) for containing said body fluid and a wall (5) surrounding said internal space (4), in which the surface of said wall (5) facing said internal space (4) of said container (1') forms a contact surface (6), and at least a part of said contact surface (6) is coated with a coating, characterized in that said coating is produced using recombinant DNA technology and comprises a polypeptide-based block copolypeptide composed of an electrically neutral, protein-repellent or charged elastin-polypeptide construct.

Citation Information

Patent Citations

  • Hirudin vacuum blood collection tube

    CN101779959A

  • Antithrombotic polyurethane elastomer and blood contact medical device using the same

    JP1987002949A

  • Anticoagulant-containing blood taking tube

    JP1997051889A

  • Blood component preservation container

    JP2001079065A

  • Substrate for preserving stem cell and blood and method for preserving the same

    JP2007209298A